Regeneron Pharmaceuticals Earnings Estimate

REGN
 Stock
  

USD 643.29  6.95  1.09%   

Many public companies, such as Regeneron Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Regeneron Pharmaceuticals' earnings estimates, investors can diagnose different trends across Regeneron Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes.
Regeneron Pharmaceuticals is projected to generate 66.87 in earnings per share on the 31st of December 2021. Regeneron Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Regeneron Pharmaceuticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Additionally, take a look at Your Equity Center.
  
Gross Profit is expected to rise to about 4.4 B this year. Profit Margin is expected to rise to 54.21 this year

Regeneron Pharmaceuticals Earnings Estimation Breakdown

Calculation of earning per share of Regeneron Pharmaceuticals is based on official Zacks consensus of 4 analysts regarding Regeneron Pharmaceuticals future annual earnings. Given the historical accuracy of 81.94%, the future earnings per share of Regeneron Pharmaceuticals is estimated to be 66.87 with the lowest and highest values of 66.37 and 67.87, respectively. Please note that this consensus of annual earnings estimates for Regeneron Pharmaceuticals is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS 62.53
66.37
Lowest
Expected EPS 66.87
67.87
Highest

Regeneron Pharmaceuticals Earnings Projection Consensus

Suppose the current estimates of Regeneron Pharmaceuticals' value are higher than the current market price of the Regeneron Pharmaceuticals stock. In this case, investors may conclude that Regeneron Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Regeneron Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

4

81.94%

62.53

66.87

Regeneron Pharmaceuticals Earnings per Share Projection vs Actual

Actual Earning per Share of Regeneron Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Regeneron Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Regeneron Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Regeneron Pharmaceuticals Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Regeneron Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Regeneron Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.

About Regeneron Pharmaceuticals Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Regeneron Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Regeneron Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Regeneron Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit1.6 B1.7 B
Earning Before Interest and Taxes EBIT1.2 B1.3 B
Earnings per Basic Share 76.40  82.43 
Earnings per Diluted Share 71.97  77.65 
Price to Earnings Ratio 38.64  41.69 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA9.7 B10.4 B
Earnings before Tax1.2 B1.3 B
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10492 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Regeneron Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Currently Active Assets on Macroaxis

Additionally, take a look at Your Equity Center. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.73
Market Capitalization
70.5 B
Quarterly Revenue Growth YOY
-0.44
Return On Assets
0.18
Return On Equity
0.32
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.